New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-

1) Kraaijpoel N et al. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis. 2018 Aug;118(8):1439-1449. DOI: 10.1055/s-0038-1667001. Epub 2018 Jul 30. 2) Khorana AA, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. 3) Hisada Y, et al. Venous Thrombosis and Cancer: from Mouse Models to Clinical Trials. Journal of Thrombosis and Haemostasis. 2015;13(8):1372-1382. 4) Imberti D et al. Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opinion on Pharmacotherapy. 2018 Jul 16:1-9. DOI: 10.1080/14656566.2018.1496238. [Epub ahead of print] 5) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer-Associated Venous Thromboembolic Disease. Version 1.2018 - March 22, 2018. 6) Khorana AA, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 16: 1-4. DOI:10.1111/jth.14219. 7) Van Es N, et al. Edoxaban for the treatment of venous thromboembolism in patients with cancer - rationale and design of the Hokusai-VTE-CANCER study. Thromb Haemost. 2015;114(6):1268-76. 8) Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia DA, et al. LBA-6 A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai-VTE-CANCER Study. Abstract presented at the Annual Society of Hematology Annual Meeting, 2017. 9) Raskob GE, van Es N, Verhamme, P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AJ, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Zhang G, Zwicker JI, Weitz JI, Buller HR. Edoxaban for the treatment of cancer-associated thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. 10) ClinicalTrials.gov. Cancer Venous Thromboembolism (VTE). Available at: https://clinicaltrials.gov/ct2/show/NCT0.... [Last accessed: July 2018].

Contact  

Lydia Worms (Europe) Daiichi Sankyo Europe GmbH Edoxaban Communications & Product PR Europe +49-(89)-7808751